Perspective Therapeutics, Inc. Corporate Presentation Update

Perspective Therapeutics, Inc. has updated its corporate presentation on September 8, 2026. The presentation details the company's advancements in radiopharmaceutical therapy for targeted oncology, highlighting three clinical-stage programs: VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for advanced solid tumors. The company emphasizes its proprietary technology, a strong intellectual property portfolio, and a manufacturing strategy designed for efficient, direct-to-hospital delivery. The presentation also outlines the significant market opportunity in targeted oncology, with an addressable market exceeding $45 billion. Preliminary clinical data for VMT-α-NET and VMT01 show promising anti-tumor activity and a favorable safety profile, supporting further development and potential registration studies. Perspective Therapeutics aims to redefine targeted oncology with its potent radiopharmaceutical payloads and a theranostic approach.